T-cell large granular lymphocyte leukemia (Cancer)

Search with Google Search with Bing
Information
Disease name
T-cell large granular lymphocyte leukemia
Disease ID
DOID:0050751
Description
"A T-cell acute lymphocytic leukemia that exhibits an unexplained, chronic (greater than 6 months) elevation in large granular lymphocytes (LGLs) in the peripheral blood." [url:http\://en.wikipedia.org/wiki/T-cell_large_granular_lymphocyte_leukemia]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
Genes Mutation Description Source Links
NCT ID Status Phase Summary Start date Completion date
NCT05010005 Active, not recruiting Phase 1 A Study of Ruxolitinib and Duvelisib in People With Lymphoma August 12, 2021 August 2025
NCT00006251 Completed Phase 1/Phase 2 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer May 2000
NCT00014235 Completed N/A Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies December 2000
NCT00025415 Completed Phase 1 Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction August 2001
NCT00040846 Completed Phase 2 Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies November 2001 December 2009
NCT00078858 Completed Phase 1/Phase 2 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant September 2003
NCT00104858 Completed Phase 2 Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma December 2004 March 30, 2018
NCT00112593 Completed N/A Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer November 1999
NCT00005799 Completed N/A Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer November 1999
NCT01093586 Completed Phase 2 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies September 2007 December 2015
NCT01129180 Completed Phase 1 Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma May 2010 December 2012
NCT01199562 Completed Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant December 2010 December 2013
NCT01254578 Completed Phase 1 Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers November 24, 2010 November 9, 2012
NCT01258998 Completed Phase 2 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma December 2010 August 2015
NCT01384513 Completed Phase 2 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies August 4, 2011 November 16, 2022
NCT01529827 Completed Phase 2 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies February 28, 2012 August 29, 2019
NCT01567709 Completed Phase 1 Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma April 16, 2012 March 29, 2018
NCT01588015 Completed Phase 1 Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant October 29, 2012 February 2, 2024
NCT01748721 Completed Phase 1 MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma November 2013 May 2015
NCT01839916 Completed Phase 2 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies April 4, 2013 August 2018
NCT01959477 Completed Early Phase 1 Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant March 2014 April 2015
NCT02168140 Completed Phase 1 CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma September 2014 September 15, 2022
NCT00458731 Completed Phase 1 Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma May 2007
NCT00608361 Completed Phase 1 Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery October 2008 August 2014
NCT00890747 Completed Phase 1 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy August 2009
NCT00898079 Completed Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer October 13, 2003 June 30, 2018
NCT01053494 Completed N/A Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer April 2010 February 2012
NCT05592015 Recruiting Phase 2 Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia May 3, 2023 December 31, 2025
NCT05141682 Recruiting Phase 1/Phase 2 Oral Azacitidine for the Treatment of Relapsed or Refractory T-cell Large Granular Lymphocytic Leukemia June 29, 2022 December 31, 2025
NCT01408043 Terminated N/A Etoposide, Filgrastim, and Plerixafor in Improving Stem Cell Mobilization in Treating Patients With Non-Hodgkin Lymphoma October 2011 May 2016
NCT01419795 Terminated Phase 2 Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant May 2012
NCT01805037 Terminated Phase 1/Phase 2 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas March 5, 2013 December 31, 2018
NCT00101205 Terminated Phase 1 Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma November 2004
NCT01088763 Terminated Phase 1 Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia March 2010 May 2011
NCT01769222 Terminated Phase 1 Ipilimumab and Local Radiation for Selected Solid Tumors February 2013 June 2015
NCT00387426 Terminated Phase 2 Sunitinib in Treating Patients With Idiopathic Myelofibrosis September 2006 February 2009
NCT01678443 Terminated Phase 1 Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies September 1, 1999 September 27, 2018
NCT00360776 Terminated Phase 2 Tipifarnib in Treating Patients With Anemia or Neutropenia and Large Granular Lymphocyte Leukemia June 2, 2006
NCT01652014 Withdrawn Phase 2 Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies January 2014 January 2017
NCT01769911 Withdrawn N/A Genetically Modified Peripheral Blood Stem Cell Transplant in Treating Patients With HIV-Associated Non-Hodgkin or Hodgkin Lymphoma February 2015
Disase is a (Disease Ontology)
DOID:5603
Cross Reference ID (Disease Ontology)
ICDO:9831/3
Cross Reference ID (Disease Ontology)
NCI:C4664
Exact Synonym (Disease Ontology)
Large granular lymphocytic leukaemia
Exact Synonym (Disease Ontology)
Large granular lymphocytic leukemia
Exact Synonym (Disease Ontology)
T-cell large granular lymphocyte leukaemia
OrphaNumber from OrphaNet (Orphanet)
86872